Speech-Language Pathologists in Highland Hts, OH Accepting Medicare

3 Speech-Language Pathologists found. Showing 1 - 3

Mrs. Joelle Grisez Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 950 Millridge Rd, Highland Hts, OH 44143 Phone: 440-995-7300

Jennifer Carter, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 962 Millridge Rd, Highland Hts, OH 44143 Phone: 440-995-7254

Cindy Ginsburg, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 415 Lowell Dr, Highland Hts, OH 44143 Phone: 440-539-1152    Fax: 440-442-8362

News Archive

Some top researchers no longer think of glaucoma solely as an eye disease

A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease.

Modulation of oral microbiota impacts the cardiovascular benefits of sport

Exercise plays a key role in maintaining good physical and mental health throughout life. There is an increasing amount of scientific evidence that some of the immune system and metabolism benefits provided by sport are related to the thousands of millions of bacteria that colonize the digestive tract, from the mouth to the intestines, known as microbiota.

Smoking cessation program prior to hip or knee replacement provides better surgical outcomes

Smokers who needed a hip or knee replacement experienced better surgical outcomes and fewer adverse events including hospital readmissions, surgical site infections and blood clots if they were enrolled in a smoking cessation program prior to surgery, according to preliminary new research that needs to be confirmed by larger studies.

Enhancements to Reaxys Medicinal Chemistry address workflow, data challenges of early drug discovery

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced enhancements to Reaxys Medicinal Chemistry that address the critical workflow and data challenges of early drug discovery.

Preliminary results from Boehringer Ingelheim's volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

Read more Medical News

› Verified 8 days ago